跳至主要内容
MedPath Trial Home
临床试验
产品
机构
资讯
AI 研究
价格
Search
EN
登录
我们重视您的隐私
我们使用 Cookie 分析网站流量并改善您的体验。请参阅我们的
隐私政策
。
拒绝
接受
Approvals
/
Health Canada
/
NAT-MONTELUKAST
Authorized
STANDARD
NAT-MONTELUKAST
natco pharma (canada) inc
🇨🇦 Health Canada
Approval Date
Jul 4, 2025
Approval ID
26905b77cd005941
Company
natco pharma (canada) inc
Type
Standard
Approval Details
Approval Id
26905b77cd005941
Drug Approval Canada Name
NAT-MONTELUKAST
Product Name
NAT-MONTELUKAST
Status
Marketed
Status Date
2022-12-19
Original Market Date
2022-12-19
Din
02522128
Drug Class
Human
Dosage Form
Tablet (Chewable)
Route Of Administration
Oral
Schedule
Prescription
Ahfs
48:10.24
Atc Original
R03DC03 MONTELUKAST
Atc Name
r 03 dc 03
Aig Number
0133823001
Company Name
natco pharma (canada) inc
Company Address
2000 Argentia Road, Plaza 1, Suite 200, Mississauga, Ontario, Canada, L5N 1P7
Active Ingredients
MONTELUKAST (MONTELUKAST SODIUM)
5 MG
Authorized
Quick Info
Agency
Health Canada
Country
🇨🇦
Approval Date
Jul 4, 2025
Approval ID
26905b77cd005941
Type
Standard
Back to Health Canada Approvals
NAT-MONTELUKAST - Health Canada Drug Approval Details